Gene · 10039
PARP3: poly(ADP-ribose) polymerase family member 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PARP3: poly(ADP-ribose) polymerase family member 3. Genes, record 10039. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10039
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9Y6F1 | Protein mono-ADP-ribosyltransferase PARP3 | 533 | 16 | Ensembl, GeneID, HGNC |
Source UniProt
Patents13
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 12759 | Q9Y6F1 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 12759 | Q9Y6F1 | Espacenet |
| JP 2024509935 A | 2024-03-05 | 49 | Q9Y6F1 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64539 | Q9Y6F1 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64540 | Q9Y6F1 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 167510 | Q9Y6F1 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 167511 | Q9Y6F1 | Espacenet |
| US 9051553 B2 | 2015-06-09 | 4 | Q9Y6F1 | Espacenet |
| US 7754459 B1 | 2010-07-13 | 4 | Q9Y6F1 | Espacenet |
| JP 2002517231 A | 2002-06-18 | 8 | Q9Y6F1 | Espacenet |
1 to 10 of 13
See all 13 patentsDrugs5
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| E-7016 | CHEMBL3527000 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| OLAPARIB | CHEMBL521686 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| RUCAPARIB | CHEMBL1173055 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| RUCAPARIB CAMSYLATE | CHEMBL3833368 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
| VELIPARIB | CHEMBL506871 | PARP 1, 2 and 3 inhibitor | INHIBITOR | ChEMBL |
Trials511
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07486687 | OLAPARIB | PHASE3 | ClinicalTrials.gov | |
| NCT07460180 | OLAPARIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07407452 | OLAPARIB | PHASE2 | ClinicalTrials.gov | |
| NCT07371104 | OLAPARIB | PHASE1 | ClinicalTrials.gov | |
| NCT07187674 | OLAPARIB | ClinicalTrials.gov | ||
| NCT07151911 | OLAPARIB | ClinicalTrials.gov | ||
| NCT07113964 | OLAPARIB | PHASE2 | ClinicalTrials.gov | |
| NCT07090369 | OLAPARIB | PHASE1 | ClinicalTrials.gov | |
| NCT07069335 | OLAPARIB | PHASE1 | ClinicalTrials.gov | |
| NCT07024784 | OLAPARIB | PHASE2 | ClinicalTrials.gov |
1 to 10 of 511
See all 511 trialsNIH grants468
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PARP3 papers | Newest fiscal year |
|---|---|---|---|
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 12 | 2025 |
| R01DK069710 | The Role of Nuclear PARPs in Signal-Regulated Transcription | 10 | 2025 |
| R01GM117275 | Protein N-terminal Methylation Mechanisms and Inhibition | 9 | 2025 |
| P30CA023168 | Cancer Center Support Grant | 7 | 2025 |
| P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| T32CA009110 | Training in Areas Fundamental to Cancer Research | 5 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 4 | 2025 |
| P20GM113117 | Chemical Biology of Infectious Disease | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 468Source NIH's project files
See all 468 nih grantsPapers882
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PARP3 Promotes SARS-CoV-2 Replication via Interaction with the Viral Nucleocapsid Protein. | Kobe J Med Sci | 2026 | 42805913 | PubTator, text mining | PubMed |
| Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors. | J Med Chem | 2026 | 42720455 | PubTator, text mining | PubMed |
| NDRG1 expression in cancers confers dependence on DNA damage repair and sensitivity to quinacrine. | Sci Signal | 2026 | 42479816 | PubTator, text mining | PubMed |
| Immunometabolic reprogramming of Mycobacterium tuberculosis-responsive memory CD4+ T cell subsets is linked to long-term protective immunity. | Front Tuberc | 2026 | 42368172 | PubTator, text mining | PubMed |
| A stage-resolved neuron-glia transcriptional atlas reveals a glial inflammatory pivot in epilepsy. | Acta Neuropathol Commun | 2026 | 42324481 | PubTator, text mining | PubMed |
| [PARP3: a Swiss army knife orchestrating DNA repair, cancer aggressiveness and cell differentiation]. | Med Sci (Paris) | 2026 | 42213971 | PubTator, text mining | PubMed |
| Molecular Insights into Parkinson's Disease Progression: A Multi-omics Analysis of the Substantia Nigra Pars Compacta across Braak Stages. | Exp Neurobiol | 2026 | 42130054 | PubTator, text mining | PubMed |
| Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition. | PLoS One | 2026 | 41931484 | PubTator, text mining | PubMed |
| Reversible RNA ADP-ribosylation on uracil bases. | Nucleic Acids Res | 2026 | 41914495 | PubTator, text mining | PubMed |
| Ultrasound-Assisted Synthesis and Biological Profiling of 1,3,5-Triazine Derivatives with Antiproliferative Activity in Triple-Negative Breast Cancer. | Curr Issues Mol Biol | 2026 | 41899470 | PubTator, text mining | PubMed |
1 to 10 of 882
See all 882 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10039
GET https://conductscience.org/api/genes/v1/10039/patents